Handelsavisen
prelaunch
Companies Healthcare IRRA.JK
IR
IRRA.JK IDX (Jakarta) Medical Equipment, Supplies & Distribution

Itama Ranoraya PT

$412,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
5,9 %
ROE
1,0 %
Net margin
2,4 %
Debt / equity
0,47
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Itama Ranoraya PT operates in the healthcare services and equipment industry, providing medical equipment, supplies, and distribution services.

Business. Itama Ranoraya PT (IRRA.JK) is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates within the Healthcare Services & Equipment sector, focusing on product sales. It is headquartered in Indonesia and is primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
1,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning IRRA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to IRRA.JK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Itama Ranoraya PT (IRRA.JK) is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates within the Healthcare Services & Equipment sector, focusing on product sales. It is headquartered in Indonesia and is primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Itama Ranoraya PT has a debt-to-equity ratio of 0.47, indicating a relatively conservative capital structure with a moderate level of leverage. The company's liquidity is assessed as medium, and its current ratio of 1.28 suggests it has sufficient short-term assets to cover its short-term liabilities, though not with a large buffer.

    The company's profitability is modest, with a return on equity of 0.97% and a return on assets of 0.38%. These figures are below the typical thresholds for strong performance in the healthcare services and equipment industry, suggesting that the company is not generating significant returns relative to its equity and asset base.

    Itama Ranoraya PT's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no detailed geographic breakdown provided. This lack of diversification could expose the company to higher risks if demand in its primary market fluctuates.

    The company's growth trajectory is not clearly defined in the available data, as there are no specific numeric deltas provided for the current or next fiscal year. However, the company's operating cash flow is negative, which may indicate challenges in generating sufficient cash from operations to support growth initiatives.

    The risk assessment for Itama Ranoraya PT highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could impact its ability to meet short-term obligations without additional financing.

    There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The absence of recent transcripts or filings suggests a lack of public disclosures that could provide further insight into the company's strategic direction or operational performance.

    Key takeaways
    • Itama Ranoraya PT has a conservative capital structure with a debt-to-equity ratio of 0.47.
    • The company's return on equity and return on assets are below typical industry benchmarks.
    • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • The company's liquidity is assessed as medium, with a current ratio of 1.28.
    • The company's operating cash flow is negative, which may impact its ability to fund operations and growth.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Debt-to-equity ratio of 0.47 is well below the 0.20 cohort median, suggesting a conservative leverage profile.

    Revenue grew 12.6% year-over-year to IDR 1.1 trillion, showing recent top-line expansion momentum.

    Net income increased 23.0% year-over-year, outpacing revenue growth and highlighting operational leverage.

    BEAR CASE · 4

    Cash conversion of -13.3% falls in the bottom quartile, signaling poor ability to turn earnings into cash.

    Return on equity of 0.97% lags the 1.42% cohort median, indicating inefficient use of shareholder capital.

    High credit risk flag suggests significant potential for loan losses or counterparty defaults impacting financial stability.

    Four-year revenue CAGR of -4.4% reveals a long-term declining trend despite recent annual growth.

    In focus — financials by report

    Valuation FY

    Market price
    $412,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $468.07B
    Net cash
    -$221.30B
    Current ratio
    1.3
    Debt / equity
    0.5
    ROA
    0.4%
    ROE
    1.0%
    Cash conversion
    -1330.0%
    CapEx / revenue
    -1.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin5,9 %Above median
    Net Margin2,4 %Below median
    ROE1,0 %Below median
    Capex / Rev-1,3 %Above P75
    D/E0,47Below median
    Cash Conv-13,30Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Itama Ranoraya PT Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    IRRA.JKCanonical
    IDX (Jakarta) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage